Imagine a world where people with diabetes could predict and prevent a life-threatening complication before it strikes. That's the promise of continuous ketone monitoring (CKM), a groundbreaking technology poised to revolutionize diabetes care. But here's where it gets exciting: a new international consensus paper, led by Breakthrough T1D and published in The Lancet Diabetes & Endocrinology, is paving the way for its widespread adoption.
This landmark paper, titled "Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology," is a game-changer. Authored by a global team of diabetes experts, including Breakthrough T1D Chief Medical Officer Thomas Danne, M.D., Dr. Ketan Dhatariya, and Dr. Richard Bergenstal, it provides the first-ever standardized guidelines for using CKM in diabetes management.
Why is this such a big deal? Diabetic ketoacidosis (DKA), a dangerous condition where ketones build up in the blood due to insulin deficiency, is a constant threat for people with diabetes. While traditional methods like blood and urine strips can detect ketones, they’re often underutilized, and predicting ketone spikes remains challenging. CKM, much like continuous glucose monitors, offers a real-time solution by continuously tracking ketone levels and alerting users to potential dangers. This could be a lifesaver, especially during illnesses like the flu, which can trigger DKA.
Dr. Thomas Danne emphasizes the transformative potential of CKM: "This technology has the power to shift diabetes care from reactive to proactive, helping individuals avoid DKA and manage their condition more safely."
And this is the part most people miss: the consensus guidance isn’t just about the technology itself. It’s a comprehensive framework that addresses everything from standardized ketone level terminology to alarm thresholds, device design, and patient education. Breakthrough T1D convened 33 experts from 14 countries to ensure these recommendations are practical, actionable, and globally applicable.
But here’s where it gets controversial: As CKM technology becomes more accessible, questions arise. Will healthcare systems prioritize its integration? How will costs be managed to ensure equitable access? And what about patient education—will everyone understand how to use this technology effectively? These are critical discussions the diabetes community needs to have.
Breakthrough T1D, formerly JDRF, is at the forefront of this movement, aligning this initiative with its mission to improve daily life for people with type 1 diabetes (T1D) while pursuing cures. T1D, an autoimmune condition affecting 9.5 million globally, requires lifelong insulin therapy and carries risks of severe complications, including DKA. Contrary to popular belief, nearly 50% of T1D diagnoses occur in adulthood, and its causes remain complex, involving both genetic and environmental factors.
As CKM technology moves closer to mainstream use, this consensus paper ensures the diabetes community is prepared. But the conversation doesn’t end here. What do you think? Will CKM live up to its promise? How can we ensure it reaches those who need it most? Share your thoughts in the comments—let’s keep the dialogue going.
